Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Food Allergy

    Current Location

    Search
    Food Allergy
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Allergy Clinical Trials

    Top Peanut Allergy Clinical Trials

    18 Celiac Disease Trials near Miami, FL

    16 Celiac Disease Trials near San Diego, CA

    14 Eczema Trials near Denver, CO

    30 Eczema Trials near Chicago, IL

    27 Adrenal Insufficiency Trials Near You

    45 Lymphedema Trials near Long Beach, CA

    Top Adenocarcinoma Clinical Trials

    Top Oligodendroglioma Clinical Trials

    Top Health Clinical Trials

    Top Acth Clinical Trials

    By Trial

    RG-RV for Cat Allergy

    Diagnostic Testing for Cephalosporin Allergy

    Diet Changes for Food Allergy

    Omalizumab-Assisted Oral Immunotherapy for Food Allergies

    Peanut Patch for Peanut Allergy

    iREACH CDS Tool for Preventing Peanut Allergy

    Oral E-B-FAHF-2 for Crohn's Disease

    Healthy Food Subsidies for Food Insecurity

    Food Safety Education for Cancer Patients

    Prepared Meals + Grocery Gift Cards for Food Insecurity

    Community Services for Healthy Living

    ASTX727 for Leukemia

    Related Searches

    Top Neuropathic-pain Clinical Trials

    Top Major-depressive-disorder Clinical Trials

    Top Anemia Clinical Trials

    Virtual Reality for Cancer Pain Management

    Genetic Counseling Interventions for Cancer Risk Management

    LYT-200 + Chemotherapy/Tislelizumab for Cancer

    SBRT for Liver Cancer

    Exercise Program for Sedentary Lifestyle

    Top Clinical Trials near Cedar City, UT

    Neurofeedback for Mild Cognitive Impairment

    Opioid-Sparing Pain Management for ACL Injury

    VITALYST System for Heart Disease

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      28 Food Allergy Trials Near You

      Power is an online platform that helps thousands of Food Allergy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Viaskin Peanut for Peanut Allergy

      Columbus, Ohio
      The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 7

      Key Eligibility Criteria

      Disqualifiers:Severe Dermatologic Disease, Uncontrolled Asthma, Others
      Must Not Be Taking:Immunotherapy, Biologics

      600 Participants Needed

      Remibrutinib for Peanut Allergy

      Columbus, Ohio
      This trial is testing a treatment to see if it can help adults with peanut allergies tolerate peanuts better. People involved in the study will take the treatment for a short period and then try eating increasing amounts of peanut protein to see if their allergic reactions are reduced. The goal is to find out if the treatment can make it safer for people with peanut allergies to eat peanuts.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      76 Participants Needed

      Long-term Ligelizumab for Food Allergy

      Cincinnati, Ohio
      This trial is testing the long-term safety and effectiveness of ligelizumab, a medication for food allergies. Ligelizumab is a new type of medication that has shown promise in treating certain allergic conditions and is now being tested for food allergies. It works by blocking proteins that trigger allergic reactions, helping to prevent symptoms. It is being tested on people who have already participated in an earlier study of this medication.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:6 - 57

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      163 Participants Needed

      Skin Barrier Cream + Fluticasone Propionate for Eczema

      Cincinnati, Ohio
      This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeram™ has been previously tested for preventing eczema in infants with a family history of allergic disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:1 - 12

      Key Eligibility Criteria

      Disqualifiers:Chronic Disease, Severe Skin Disorder, Food Allergies, Others

      398 Participants Needed

      Peanut Patch for Peanut Allergy

      Cincinnati, Ohio
      The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:1 - 3

      Key Eligibility Criteria

      Disqualifiers:Severe Anaphylaxis, Immunotherapy, Asthma, Others
      Must Not Be Taking:Monoclonal Antibodies, Biologics

      480 Participants Needed

      Skin Patch Test for Irritable Bowel Syndrome

      Barboursville, West Virginia
      Participants with IBS are skin patch tested (no needles) to 80 different foods and food additives, compounded for patch testing, in search of food allergies. The testing requires 3 office visits within a 4 or 5 day period. The patches are taped to the back at Visit #. At Visit #2 48 hours later, the patches are removed from the skin and the outside border of each patch is marked with a felt tip marker. At Visit #3 (final visit) 1 or 2 days later, the patch test reading is performed by the doctor-investigator. An allergy is identified as a small red mark where the food was in contact with the skin for 48 hours. Those participants found to have food allergies are then placed on an avoidance diet (no calorie restriction) for 16 weeks where they either avoid eating the food(s) to which they are allergic (the \"true\" avoidance diet) or food(s) to which the testing did not show an allergy (this is called the \"sham\" avoidance diet). There is a 50/50 chance of going on either avoidance diet. The avoidance diet is assigned in such a way that neither the participant or the doctor-investigator knows which diet is being followed. After the 16 weeks, the participants answers a brief online questionnaire that asks about the IBS symptoms while following the avoidance diet. After the 16 week avoidance diet and final questionnaire are completed, those participants who were on the sham diet will be told of their true food allergies which they may try avoiding on their own.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Rash, Gastrointestinal Disease, Others
      Must Not Be Taking:Cortisone, Immunosuppressants, Opiates, Others

      250 Participants Needed

      Dried Plums for Postmenopausal Health

      Indianapolis, Indiana
      Prior studies have shown that dietary supplementation with dried plums (also known as prunes) reduces bone loss in postmenopausal women. The purpose of this clinical trial is to understand how dried plums mediate their effects on bone. The main questions the study will answer are: 1. Does adding dried plums to the diet alter immune cell function? 2. Does dried plum alter gut microbes? 3. Does a person's vitamin D status influence this response? Researcher will compare the response following consumption of the normal diet to supplementing the diet with dried plums. Participant will: 1. Consume their normal diet or supplement their normal diet dried plums for four week periods over the course of 3-4 months. 2. Complete 5 study visits scheduled. 3. Perform some physical function tests and have a bone density scan at the beginning of the study. 4. Complete questionnaires, a 3-day food record, and provide stool and blood samples at 4 different timepoints during the study. 5. Record information about their bowel habits
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:60 - 75
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Osteoporosis, Diabetes, Cancer, Others
      Must Not Be Taking:Bisphosphonates, Steroids, Biologics, Others

      30 Participants Needed

      Molecular Analysis of Eczema and Food Allergy

      Ann Arbor, Michigan
      This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various times during the oral food challenge. This study will create a molecular map of the pathology of atopic dermatitis and food allergy. This information will be deployed to evaluate the hypothesis that atopic dermatitis and food allergy share unique genetic transcriptional signals in which the study team can then further analyze pathological pathways and cell types.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:10 - 55

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Cancer, Pulmonary, Others
      Must Not Be Taking:Antihistamines, Biologics

      200 Participants Needed

      iREACH CDS Tool for Preventing Peanut Allergy

      Danville, Illinois
      iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines. iREACH has been developed as an electronic health record (EHR) integrated Clinical Decision Support (CDS) tool together with educational modules on the PPA guidelines to assist clinicians in implementing the 2017 NIAID PPA Guidelines. A practice-based, two-arm, cluster-randomized clinical trial will evaluate the effectiveness of iREACH in increasing pediatric clinician adherence to the PPA Guidelines and explore the end-goal of reducing peanut allergy incidence by age 2.5 years in the intervention vs control group. This study has the potential to: 1) provide evidence regarding the effectiveness of iREACH in promoting clinical processes and outcomes related to the PPA Guidelines, 2) provide important insight about practice-based implementation of PPA Guidelines by pediatric clinicians, allergists and caregivers, and 3) facilitate rapid, widespread implementation of PPA Guidelines and reduce peanut allergy incidence across the US.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:4+

      Key Eligibility Criteria

      Disqualifiers:Dysphagia, Muscular Dystrophy, Gastrectomy, Others

      30 Participants Needed

      Prebiotics for Peanut Allergy

      Hyde Park, Illinois
      The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy. The prebiotic is not an FDA approved drug or medication rather a fiber found at local grocery stores.
      Stay on current meds

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Chronic Disease, Autoimmune, Cardiovascular, Others
      Must Not Be Taking:Oral Steroids, Biologics

      30 Participants Needed

      Omalizumab-Assisted Oral Immunotherapy for Food Allergies

      Toronto, Ontario
      This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance dose. Two dosages of omalizumab will be compared to placebo during an oral immunotherapy protocol for three simultaneous food allergens.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:6 - 25

      Key Eligibility Criteria

      Disqualifiers:Severe Asthma, Eosinophilic Oesophagitis, Others
      Must Not Be Taking:Immunosuppressants, Beta-blockers, ACE Inhibitors

      90 Participants Needed

      IgE Threshold Testing for Food Allergy

      Bethesda, Maryland
      Background: Atopic dermatitis (AD), also called eczema, makes skin dry, red, and itchy. People with AD are more likely to get a food allergy than people without AD. But some food allergy tests are not always accurate in people with AD. Researchers want to study if people are truly allergic to milk and/or peanuts. Objectives: To improve the ways doctors test for food allergy in people with AD. Eligibility: People ages 3-21 who have had AD; have a high total IgE level (an allergic antibody); might have a milk and/or peanut allergy; and are currently enrolled in another NIH study Design: Participants will be screened under another protocol. Participants will have a physical exam, blood tests, and medical history. Participants will breathe into a plastic device that measures lung strength. Participants may get a small plastic tube inserted in their arm. Participants who have not had an allergic reaction to food in the past 3 years will do 1 or more oral food challenge (OFCs) depending on their allergies. They will eat a little bit of the food they might be allergic to. They will be watched for a reaction. If they have one, they will know for sure they are allergic. They may keep eating bigger portions of the food until they either have a reaction or finish all the food. In some OFCs, participants will get a placebo food. OFCs will last a few hours or 2 days. Participants will repeat all tests at each OFC. Participation can last up to 12 months. ...

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:3 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiac Disease, Eosinophilic GI, Others
      Must Not Be Taking:Beta-blockers, Omalizumab, Dupilumab

      200 Participants Needed

      Low-Dose Multi-Oral Immunotherapy for Food Allergies

      Toronto, Ontario
      This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:6 - 15

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      18 Participants Needed

      Food Allergy Mastery Program for Food Allergies

      Washington D.C., District of Columbia
      The proposed research project will evaluate a novel behavioral intervention that promotes early adolescent food allergy self-management and adjustment through 1) food allergy education, 2) problem-solving, communication, assertiveness, and anxiety management skill building, and 3) peer support.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:10 - 14

      Key Eligibility Criteria

      Disqualifiers:Non-IgE Food Allergy, Intolerance, Non-atopic Illness, Pervasive Developmental Disorder, Others

      240 Participants Needed

      Omalizumab for Food Allergy

      Baltimore, Maryland
      In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:1 - 55

      Key Eligibility Criteria

      Disqualifiers:Severe Asthma, Anaphylaxis, Cancer, Others
      Must Not Be Taking:Corticosteroids, Antidepressants, Beta-blockers, Others

      32 Participants Needed

      Omalizumab for Peanut Allergy

      Baltimore, Maryland
      This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergic to more than two other foods, the primary endpoint/outcome in this study will only be assessed in peanut and two other foods for each participant. The primary objective of the study is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC), after treatment with either omalizumab or placebo for omalizumab.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:1 - 55

      Key Eligibility Criteria

      Disqualifiers:Severe Asthma, Anaphylaxis, Cancer, Others
      Must Not Be Taking:Corticosteroids, Antidepressants, Beta-blockers

      471 Participants Needed

      Sublingual Immunotherapy for Nut Allergies

      Chapel Hill, North Carolina
      The CASCADES study will investigate the safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of cashew allergy in children ages 1-11 years old. Primary efficacy will be assessed after 18 months of cashew SLIT. Lab studies and an oral food challenge after 6 months of cashew SLIT will help determine how quickly cashew SLIT begins to take effect.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2
      Age:1 - 11

      Key Eligibility Criteria

      Disqualifiers:Severe Asthma, Anaphylaxis, Eosinophilic Disease, Others
      Must Not Be Taking:Monoclonal Antibodies

      45 Participants Needed

      Omalizumab for Food Allergy

      Chapel Hill, North Carolina
      This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:1 - 55

      Key Eligibility Criteria

      Disqualifiers:Severe Asthma, Severe Anaphylaxis, Cancer, Others
      Must Not Be Taking:Corticosteroids, Tricyclics, Beta-blockers

      30 Participants Needed

      Maternal Diet for Preventing Food Allergies

      Rochester, New York
      Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 40
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Renal/liver/cardiac Insufficiency, Others
      Must Not Be Taking:Immunosuppressants

      500 Participants Needed

      IN-001 Sublingual Spray for Anaphylaxis

      St Louis, Missouri
      This is an open-label, two-part study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as a single dose of L-dipivefrin (IN-001) sublingual spray in healthy adults. For both parts of the study, participants will undergo at least 10 hours of fasting prior to dosing. Part 1 of the study focuses on IN-001 dose/formulation exploration in a small number of participants (N=6) to help select the most appropriate dose/formulation to be used in Part 2 of the study in a larger number of participants (N=24).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Hepatitis, Alcoholism, Others
      Must Not Be Taking:Antidepressants, Antihypertensives, Antihistamines, Others

      30 Participants Needed

      Why Other Patients Applied

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51
      Match to a Food Allergy Trial

      Linvoseltamab + Dupilumab for Food Allergy

      Philadelphia, Pennsylvania
      This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like peanuts, milk, shellfish) by making antibodies called IgE. An antibody is a protein that allows the immune system to find and fight off things the body does not recognize (allergens). IgE antibodies are sent out by cells like plasma cells. These antibodies and allergens bind to other cells that send out chemicals, causing an allergic reaction. The aim of the study is to see what side effects happen when linvoseltamab is combined with dupilumab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * Does linvoseltamab combined with dupilumab affect other types of antibodies in the blood at different times * How much study drug(s) is in the blood at different times
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Chronic Disease, Asthma, Others
      Must Be Taking:Dupilumab

      6 Participants Needed

      Diet Changes for Food Allergy

      Philadelphia, Pennsylvania
      The objective of this study is to determine the performance characteristics of a series of novel, non-invasive allergen-activated T cell assays designed to identify Eosinophilic esophagitis (EoE) causal foods, when used in conjunction with standard-of-care (SOC) practices. The question it aims to answer is: Will assay results accurately predict EoE food allergies in concordance with SOC endoscopies after diet changes?
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:0 - 90

      Key Eligibility Criteria

      Disqualifiers:PPI-responsive EoE, Other GI Diseases, Others
      Must Not Be Taking:Immunomodulatory Therapy

      50 Participants Needed

      Ready. Set. Food! for Preventing Food Allergies

      New York, New York
      Multiple clinical trials have demonstrated that early allergen introduction, feeding babies common food allergens before six months, decreases children's risk of developing a food allergy. Despite successful food allergy introduction trials showing that food allergies can be prevented, early introduction in the required amount can be challenging for parents. In some studies, less than 20% of parents introduce peanuts before their child is six months old, and few feed them regularly after introduction. Ready. Set. Food! is a direct-to-consumer product that offers a convenient supplement with a daily dose regimen that can be added to breastmilk, formula, or food to make early allergen introduction easy. The formulation includes cow's milk, egg, and peanut, representing the majority of childhood food allergies, and the protein levels are based on doses found to be effective in clinical trials. Over 200,000 infants have used Ready. Set. Food!. This study investigates the effectiveness of introducing common allergens to infants with the goal of preventing food allergies. The study will enroll 1,100 infants stratified by their risk of developing a food allergy who are assigned to either receive Ready. Set. Food! supplements or follow standard allergen introduction practices recommended by their pediatrician. The goal of this study is to assess how Ready. Set. Food! allergen introduction supplements improve the experience of parents introducing allergens, decrease healthcare costs related to food allergies, and decrease food allergy prevalence.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:2 - 5

      Key Eligibility Criteria

      Disqualifiers:Allergy To Egg, Milk, Peanut, Others
      Must Not Be Taking:Antibiotics

      1110 Participants Needed

      Oral Food Challenge for Food Intolerance

      New York, New York
      This is a phase I multicenter clinical trial that aims to find the optimal dose for conducting a novel low-dose, multi-day oral food challenge (OFC) protocol for diagnosing food protein-induced enterocolitis syndrome (FPIES). Individuals ages 1-60 years with a history of suspected or confirmed FPIES will be eligible for enrollment. Recruitment is expected to occur over 3 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:1 - 60

      Key Eligibility Criteria

      Disqualifiers:Severe FPIES, Eosinophilic Disorders, Asthma, Others
      Must Not Be Taking:Systemic Steroids, Biologic Drugs

      72 Participants Needed

      Abrocitinib for Food Allergy

      New York, New York
      This study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. Abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in many patients with multiple atopic conditions.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Allergy To Abrocitinib, Others
      Must Not Be Taking:Dupilumab, Biologics, Steroids, Others

      40 Participants Needed

      Salbutamol Inhaler for Allergic Abdominal Pain

      Montréal, Quebec
      The goal of this study is to assess the efficacy of inhaled salbutamol to treat abdominal pain during food allergic reactions. Patients experiencing abominal pain as a result of a food allergic reaction during a food challenge in the allergy clinic will be invited to participate to the study. They will receive either 8 puffs of salbutamol (asthma inhaler) or 8 puffs of a placebo inhaler. The abdominal pain will then be followed using a numeric scale to see if patients receiving the medication experienced a faster improvement compared to those receiving the placebo.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:6 - 55

      Key Eligibility Criteria

      Disqualifiers:Adverse Reaction To Salbutamol, Hypersensitivity, Hyperglycemia, Arrhythmia, Others
      Must Not Be Taking:Beta-blockers, Long-acting Beta Agonists

      498 Participants Needed

      Cognitive Behavioral Therapy for Parents of Children With Food Allergies

      Kansas City, Missouri
      Parents of children with food allergies that are medically established will be able to participate in 6 one-hour weekly virtual Cognitive Behavioral Therapy (CBT) groups, and outcomes will be measured for anxiety, depression and quality of life. Possible benefits include improvement in psychological functioning and quality of life of families, as well as improved understanding of the use of group Cognitive Behavioral Therapy (CBT) for parents of children with medically established food allergies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicidal Ideation, Substance Abuse, Others
      Must Be Taking:Antidepressants, Anxiety Medications

      10 Participants Needed

      Microbiota Transplantation for Peanut Allergy

      Boston, Massachusetts
      This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective for Part A is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from \<=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation. The primary objective for Part B is to evaluate whether MTT with antibiotic pretreatment can lead to sustained unresponsiveness (SU) defined as tolerating the same dose of peanut protein administered during a food challenge at baseline and 12 weeks after OIT cessation.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Anaphylaxis, Chronic Infections, GI Conditions, Others
      Must Not Be Taking:Immunosuppressants, Omalizumab, Dupilumab, Corticosteroids

      37 Participants Needed

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Food Allergy clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Food Allergy clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Food Allergy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Food Allergy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Food Allergy medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Food Allergy clinical trials?

      Most recently, we added Sublingual Immunotherapy for Nut Allergies, Diet Changes for Food Allergy and IN-001 Sublingual Spray for Anaphylaxis to the Power online platform.